chr10-133310212-G-A

Variant summary

Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4_Moderate

The NM_145806.4(ZNF511):​c.478G>A​(p.Asp160Asn) variant causes a missense change. The variant allele was found at a frequency of 0.000158 in 1,613,958 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: 𝑓 0.00011 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00016 ( 0 hom. )

Consequence

ZNF511
NM_145806.4 missense

Scores

6
13

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 5.66

Publications

2 publications found
Variant links:
Genes affected
ZNF511 (HGNC:28445): (zinc finger protein 511) Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in nucleus. Predicted to be part of chromatin. [provided by Alliance of Genome Resources, Apr 2022]
ZNF511-PRAP1 (HGNC:38088): (ZNF511-PRAP1 readthrough) This locus represents naturally occurring readthrough transcription between the neighboring ZNF511 (zinc finger protein 511) and PRAP1 (proline-rich acidic protein 1) genes on chromosome 10. The putative readthrough transcript may encode a fusion protein that shares sequence identity with each individual gene product and may be involved in the regulation of gene promoters, particularly those found on transfected plasmids. [provided by RefSeq, Apr 2017]
TUBGCP2 (HGNC:18599): (tubulin gamma complex component 2) Predicted to enable gamma-tubulin binding activity. Predicted to contribute to microtubule minus-end binding activity. Involved in brain development and neuron migration. Located in centrosome and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2022]
TUBGCP2 Gene-Disease associations (from GenCC):
  • Norman-Roberts syndrome
    Inheritance: AR Classification: STRONG Submitted by: PanelApp Australia
  • pachygyria, microcephaly, developmental delay, and dysmorphic facies, with or without seizures
    Inheritance: AR Classification: STRONG, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -2 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.11575517).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ZNF511NM_145806.4 linkc.478G>A p.Asp160Asn missense_variant Exon 4 of 6 ENST00000361518.10 NP_665805.2 Q8NB15-2
ZNF511-PRAP1NM_001396060.1 linkc.478G>A p.Asp160Asn missense_variant Exon 4 of 9 NP_001382989.1
ZNF511NR_130127.2 linkn.508G>A non_coding_transcript_exon_variant Exon 4 of 6
TUBGCP2NR_046330.2 linkn.718+1408C>T intron_variant Intron 1 of 17

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ZNF511ENST00000361518.10 linkc.478G>A p.Asp160Asn missense_variant Exon 4 of 6 1 NM_145806.4 ENSP00000355251.5 Q8NB15-2
ZNF511-PRAP1ENST00000368554.8 linkc.304G>A p.Asp102Asn missense_variant Exon 3 of 8 2 ENSP00000357542.5 H7BY64

Frequencies

GnomAD3 genomes
AF:
0.000105
AC:
16
AN:
152256
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000262
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.0000941
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000147
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000167
AC:
42
AN:
251434
AF XY:
0.000118
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.000549
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0000462
Gnomad NFE exome
AF:
0.000176
Gnomad OTH exome
AF:
0.000326
GnomAD4 exome
AF:
0.000164
AC:
239
AN:
1461702
Hom.:
0
Cov.:
32
AF XY:
0.000157
AC XY:
114
AN XY:
727130
show subpopulations
African (AFR)
AF:
0.0000299
AC:
1
AN:
33480
American (AMR)
AF:
0.000470
AC:
21
AN:
44722
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.0000348
AC:
3
AN:
86254
European-Finnish (FIN)
AF:
0.0000939
AC:
5
AN:
53250
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5764
European-Non Finnish (NFE)
AF:
0.000182
AC:
202
AN:
1112004
Other (OTH)
AF:
0.000116
AC:
7
AN:
60392
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.474
Heterozygous variant carriers
0
15
30
45
60
75
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000105
AC:
16
AN:
152256
Hom.:
0
Cov.:
33
AF XY:
0.0000807
AC XY:
6
AN XY:
74382
show subpopulations
African (AFR)
AF:
0.0000241
AC:
1
AN:
41468
American (AMR)
AF:
0.000262
AC:
4
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5196
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4836
European-Finnish (FIN)
AF:
0.0000941
AC:
1
AN:
10626
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.000147
AC:
10
AN:
68048
Other (OTH)
AF:
0.00
AC:
0
AN:
2094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.556
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000152
Hom.:
0
Bravo
AF:
0.000113
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000116
AC:
1
ExAC
AF:
0.000206
AC:
25
EpiCase
AF:
0.0000545
EpiControl
AF:
0.000237

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not specified Uncertain:1
Sep 11, 2024
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.478G>A (p.D160N) alteration is located in exon 4 (coding exon 4) of the ZNF511 gene. This alteration results from a G to A substitution at nucleotide position 478, causing the aspartic acid (D) at amino acid position 160 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.14
BayesDel_addAF
Benign
-0.48
T
BayesDel_noAF
Benign
-0.58
CADD
Pathogenic
27
DANN
Uncertain
1.0
DEOGEN2
Benign
0.048
T;.
Eigen
Uncertain
0.66
Eigen_PC
Uncertain
0.66
FATHMM_MKL
Uncertain
0.97
D
LIST_S2
Uncertain
0.91
D;D
M_CAP
Benign
0.0084
T
MetaRNN
Benign
0.12
T;T
MetaSVM
Benign
-0.53
T
MutationAssessor
Benign
1.9
L;L
PhyloP100
5.7
PrimateAI
Benign
0.34
T
PROVEAN
Benign
-1.9
N;N
REVEL
Benign
0.14
Sift
Benign
0.11
T;T
Sift4G
Uncertain
0.020
D;D
Polyphen
0.98
D;.
Vest4
0.34
MVP
0.061
MPC
0.43
ClinPred
0.11
T
GERP RS
5.4
Varity_R
0.071
gMVP
0.32
Mutation Taster
=87/13
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs199668244; hg19: chr10-135123716; API